David A. Siegel Theravance Biopharma, Inc. Transaction History

Two Sigma Advisers, LP

  • $41.3 Billion
  • Q3 2024

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024
BUY
$8.29 - $9.92 $281,031 - $336,288
33,900 New
33,900 $287,000
Q2 2023

Aug 14, 2023
SELL
$10.16 - $11.92 $3.96 Million - $4.64 Million
-389,500 Reduced 80.51%
94,300 $976,000
Q1 2023

May 15, 2023
SELL
$9.87 - $11.44 $5.18 Million - $6 Million
-524,800 Reduced 52.03%
483,800 $5.25 Million
Q4 2022

Feb 14, 2023
BUY
$9.65 - $11.34 $3.01 Million - $3.54 Million
312,000 Added 44.79%
1,008,600 $11.3 Million
Q3 2022

Nov 14, 2022
BUY
$8.39 - $10.22 $5.84 Million - $7.12 Million
696,600 New
696,600 $7.06 Million
Q2 2022

Aug 15, 2022
SELL
$8.41 - $10.34 $89,987 - $110,638
-10,700 Closed
0 $0
Q1 2022

May 16, 2022
BUY
$8.33 - $12.96 $89,131 - $138,672
10,700 New
10,700 $102,000
Q2 2021

Aug 16, 2021
SELL
$14.52 - $22.46 $432,696 - $669,308
-29,800 Closed
0 $0
Q1 2021

May 17, 2021
SELL
$16.57 - $21.08 $119,304 - $151,776
-7,200 Reduced 19.46%
29,800 $608,000
Q4 2020

Feb 16, 2021
SELL
$14.89 - $20.16 $637,292 - $862,848
-42,800 Reduced 53.63%
37,000 $657,000
Q3 2020

Nov 16, 2020
BUY
$14.79 - $22.49 $420,036 - $638,716
28,400 Added 55.25%
79,800 $1.18 Million
Q2 2020

Aug 14, 2020
BUY
$20.64 - $30.69 $1.06 Million - $1.58 Million
51,400 New
51,400 $1.08 Million

Others Institutions Holding TBPH

# of Institutions
122
Shares Held
47.3M
Call Options Held
200
Put Options Held
12.8K
View Full List

About Theravance Biopharma, Inc.

TBPH Quotes by TradingView
  • Ticker TBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,782,400
  • Market Cap $642M
  • Description
  • Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...
More about TBPH
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email